Browse RBPJ

Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Mainly nuclear, upon interaction with RITA/C12orf52, translocates to the cytoplasm, down-regulating the Notch signaling pathway.
Domain PF09270 Beta-trefoil DNA-binding domain
PF09271 LAG1
Function

Transcriptional regulator that plays a central role in Notch signaling, a signaling pathway involved in cell-cell communication that regulates a broad spectrum of cell-fate determinations. Acts as a transcriptional repressor when it is not associated with Notch proteins. When associated with some NICD product of Notch proteins (Notch intracellular domain), it acts as a transcriptional activator that activates transcription of Notch target genes. Probably represses or activates transcription via the recruitment of chromatin remodeling complexes containing histone deacetylase or histone acetylase proteins, respectively. Specifically binds to the immunoglobulin kappa-type J segment recombination signal sequence. Binds specifically to methylated DNA (PubMed:21991380). Binds to the oxygen responsive element of COX4I2 and activates its transcription under hypoxia conditions (4% oxygen) (PubMed:23303788). Negatively regulates the phagocyte oxidative burst in response to bacterial infection by repressing transcription of NADPH oxidase subunits (By similarity).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0001701 in utero embryonic development
GO:0001708 cell fate specification
GO:0001756 somitogenesis
GO:0001773 myeloid dendritic cell activation
GO:0001837 epithelial to mesenchymal transition
GO:0001890 placenta development
GO:0001892 embryonic placenta development
GO:0001942 hair follicle development
GO:0001974 blood vessel remodeling
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002274 myeloid leukocyte activation
GO:0002437 inflammatory response to antigenic stimulus
GO:0002521 leukocyte differentiation
GO:0002573 myeloid leukocyte differentiation
GO:0003002 regionalization
GO:0003007 heart morphogenesis
GO:0003128 heart field specification
GO:0003139 secondary heart field specification
GO:0003151 outflow tract morphogenesis
GO:0003157 endocardium development
GO:0003158 endothelium development
GO:0003159 morphogenesis of an endothelium
GO:0003160 endocardium morphogenesis
GO:0003197 endocardial cushion development
GO:0003198 epithelial to mesenchymal transition involved in endocardial cushion formation
GO:0003203 endocardial cushion morphogenesis
GO:0003205 cardiac chamber development
GO:0003206 cardiac chamber morphogenesis
GO:0003208 cardiac ventricle morphogenesis
GO:0003214 cardiac left ventricle morphogenesis
GO:0003222 ventricular trabecula myocardium morphogenesis
GO:0003229 ventricular cardiac muscle tissue development
GO:0003231 cardiac ventricle development
GO:0003256 regulation of transcription from RNA polymerase II promoter involved in myocardial precursor cell differentiation
GO:0003272 endocardial cushion formation
GO:0003306 Wnt signaling pathway involved in heart development
GO:0003307 regulation of Wnt signaling pathway involved in heart development
GO:0006310 DNA recombination
GO:0006352 DNA-templated transcription, initiation
GO:0006367 transcription initiation from RNA polymerase II promoter
GO:0006959 humoral immune response
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007219 Notch signaling pathway
GO:0007221 positive regulation of transcription of Notch receptor target
GO:0007389 pattern specification process
GO:0007423 sensory organ development
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0008544 epidermis development
GO:0009306 protein secretion
GO:0009912 auditory receptor cell fate commitment
GO:0009913 epidermal cell differentiation
GO:0009952 anterior/posterior pattern specification
GO:0009957 epidermal cell fate specification
GO:0010002 cardioblast differentiation
GO:0010092 specification of animal organ identity
GO:0010453 regulation of cell fate commitment
GO:0010455 positive regulation of cell fate commitment
GO:0014706 striated muscle tissue development
GO:0014855 striated muscle cell proliferation
GO:0016055 Wnt signaling pathway
GO:0016202 regulation of striated muscle tissue development
GO:0019827 stem cell population maintenance
GO:0021536 diencephalon development
GO:0021700 developmental maturation
GO:0021983 pituitary gland development
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0030098 lymphocyte differentiation
GO:0030099 myeloid cell differentiation
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030183 B cell differentiation
GO:0030216 keratinocyte differentiation
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030509 BMP signaling pathway
GO:0030510 regulation of BMP signaling pathway
GO:0030513 positive regulation of BMP signaling pathway
GO:0030900 forebrain development
GO:0032633 interleukin-4 production
GO:0033002 muscle cell proliferation
GO:0035019 somatic stem cell population maintenance
GO:0035051 cardiocyte differentiation
GO:0035239 tube morphogenesis
GO:0035265 organ growth
GO:0035270 endocrine system development
GO:0035282 segmentation
GO:0035315 hair cell differentiation
GO:0035904 aorta development
GO:0035907 dorsal aorta development
GO:0035909 aorta morphogenesis
GO:0035912 dorsal aorta morphogenesis
GO:0036003 positive regulation of transcription from RNA polymerase II promoter in response to stress
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0036302 atrioventricular canal development
GO:0038127 ERBB signaling pathway
GO:0040034 regulation of development, heterochronic
GO:0042113 B cell activation
GO:0042303 molting cycle
GO:0042490 mechanoreceptor differentiation
GO:0042491 auditory receptor cell differentiation
GO:0042633 hair cycle
GO:0042692 muscle cell differentiation
GO:0042693 muscle cell fate commitment
GO:0042742 defense response to bacterium
GO:0043011 myeloid dendritic cell differentiation
GO:0043583 ear development
GO:0043588 skin development
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0045165 cell fate commitment
GO:0045445 myoblast differentiation
GO:0045446 endothelial cell differentiation
GO:0045844 positive regulation of striated muscle tissue development
GO:0045927 positive regulation of growth
GO:0046620 regulation of organ growth
GO:0046622 positive regulation of organ growth
GO:0048013 ephrin receptor signaling pathway
GO:0048505 regulation of timing of cell differentiation
GO:0048514 blood vessel morphogenesis
GO:0048568 embryonic organ development
GO:0048608 reproductive structure development
GO:0048634 regulation of muscle organ development
GO:0048636 positive regulation of muscle organ development
GO:0048638 regulation of developmental growth
GO:0048639 positive regulation of developmental growth
GO:0048644 muscle organ morphogenesis
GO:0048645 animal organ formation
GO:0048663 neuron fate commitment
GO:0048732 gland development
GO:0048733 sebaceous gland development
GO:0048738 cardiac muscle tissue development
GO:0048762 mesenchymal cell differentiation
GO:0048771 tissue remodeling
GO:0048820 hair follicle maturation
GO:0048839 inner ear development
GO:0048844 artery morphogenesis
GO:0048863 stem cell differentiation
GO:0050663 cytokine secretion
GO:0051146 striated muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051149 positive regulation of muscle cell differentiation
GO:0051153 regulation of striated muscle cell differentiation
GO:0051155 positive regulation of striated muscle cell differentiation
GO:0055007 cardiac muscle cell differentiation
GO:0055008 cardiac muscle tissue morphogenesis
GO:0055010 ventricular cardiac muscle tissue morphogenesis
GO:0055017 cardiac muscle tissue growth
GO:0055021 regulation of cardiac muscle tissue growth
GO:0055023 positive regulation of cardiac muscle tissue growth
GO:0055024 regulation of cardiac muscle tissue development
GO:0055025 positive regulation of cardiac muscle tissue development
GO:0060038 cardiac muscle cell proliferation
GO:0060043 regulation of cardiac muscle cell proliferation
GO:0060045 positive regulation of cardiac muscle cell proliferation
GO:0060070 canonical Wnt signaling pathway
GO:0060113 inner ear receptor cell differentiation
GO:0060120 inner ear receptor cell fate commitment
GO:0060317 cardiac epithelial to mesenchymal transition
GO:0060379 cardiac muscle cell myoblast differentiation
GO:0060415 muscle tissue morphogenesis
GO:0060419 heart growth
GO:0060420 regulation of heart growth
GO:0060421 positive regulation of heart growth
GO:0060428 lung epithelium development
GO:0060479 lung cell differentiation
GO:0060485 mesenchyme development
GO:0060486 Clara cell differentiation
GO:0060487 lung epithelial cell differentiation
GO:0060537 muscle tissue development
GO:0060541 respiratory system development
GO:0060562 epithelial tube morphogenesis
GO:0060563 neuroepithelial cell differentiation
GO:0060674 placenta blood vessel development
GO:0060711 labyrinthine layer development
GO:0060716 labyrinthine layer blood vessel development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0060837 blood vessel endothelial cell differentiation
GO:0060839 endothelial cell fate commitment
GO:0060840 artery development
GO:0060842 arterial endothelial cell differentiation
GO:0060844 arterial endothelial cell fate commitment
GO:0060846 blood vessel endothelial cell fate commitment
GO:0060847 endothelial cell fate specification
GO:0060911 cardiac cell fate commitment
GO:0060914 heart formation
GO:0060923 cardiac muscle cell fate commitment
GO:0061053 somite development
GO:0061154 endothelial tube morphogenesis
GO:0061311 cell surface receptor signaling pathway involved in heart development
GO:0061314 Notch signaling involved in heart development
GO:0061316 canonical Wnt signaling pathway involved in heart development
GO:0061317 canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment
GO:0061323 cell proliferation involved in heart morphogenesis
GO:0061383 trabecula morphogenesis
GO:0061384 heart trabecula morphogenesis
GO:0061418 regulation of transcription from RNA polymerase II promoter in response to hypoxia
GO:0061419 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia
GO:0061458 reproductive system development
GO:0070482 response to oxygen levels
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071695 anatomical structure maturation
GO:0071772 response to BMP
GO:0071773 cellular response to BMP stimulus
GO:0072132 mesenchyme morphogenesis
GO:0072148 epithelial cell fate commitment
GO:0072554 blood vessel lumenization
GO:0072602 interleukin-4 secretion
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0097028 dendritic cell differentiation
GO:0097101 blood vessel endothelial cell fate specification
GO:0098542 defense response to other organism
GO:0098727 maintenance of cell number
GO:0098773 skin epidermis development
GO:0198738 cell-cell signaling by wnt
GO:1901184 regulation of ERBB signaling pathway
GO:1901186 positive regulation of ERBB signaling pathway
GO:1901187 regulation of ephrin receptor signaling pathway
GO:1901189 positive regulation of ephrin receptor signaling pathway
GO:1901213 regulation of transcription from RNA polymerase II promoter involved in heart development
GO:1901295 regulation of canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment
GO:1901297 positive regulation of canonical Wnt signaling pathway involved in cardiac muscle cell fate commitment
GO:1901522 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus
GO:1901861 regulation of muscle tissue development
GO:1901863 positive regulation of muscle tissue development
GO:1905066 regulation of canonical Wnt signaling pathway involved in heart development
GO:1905068 positive regulation of canonical Wnt signaling pathway involved in heart development
GO:1905207 regulation of cardiocyte differentiation
GO:1905209 positive regulation of cardiocyte differentiation
GO:2000027 regulation of organ morphogenesis
GO:2000136 regulation of cell proliferation involved in heart morphogenesis
GO:2000138 positive regulation of cell proliferation involved in heart morphogenesis
GO:2000725 regulation of cardiac muscle cell differentiation
GO:2000727 positive regulation of cardiac muscle cell differentiation
GO:2000826 regulation of heart morphogenesis
Molecular Function GO:0000150 recombinase activity
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001085 RNA polymerase II transcription factor binding
GO:0001103 RNA polymerase II repressing transcription factor binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0008134 transcription factor binding
GO:0047485 protein N-terminus binding
GO:0070491 repressing transcription factor binding
Cellular Component GO:0002193 MAML1-RBP-Jkappa- ICN1 complex
GO:0005667 transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa04330 Notch signaling pathway
Reactome R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-157052: NICD traffics to nucleus
R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-2197563: NOTCH2 intracellular domain regulates transcription
R-HSA-350054: Notch-HLH transcription pathway
R-HSA-1912422: Pre-NOTCH Expression and Processing
R-HSA-1912408: Pre-NOTCH Transcription and Translation
R-HSA-186712: Regulation of beta-cell development
R-HSA-210744: Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
R-HSA-1980145: Signaling by NOTCH2
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RBPJ and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RBPJ and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20420708Melanoma; Lung Carcinoma; Sarcoma; Hepatocellular CarcinomaPromote immunityIndeed, tumors containing the RBP-J deficient DCs had fewer infiltrating T-cells, B-cells and NK-cells. At the molecular level, the RBP-J deficient DCs expressed lower MHC II, CD80, CD86, and CCR7, resulting in inefficient DC migration and T-cell activation in vitro and in vivo. The RBP-J-mediated Notch signaling is essential for DC-dependent anti-tumor immune responses. The deficiency of RBP-J impairs the DC-based anti-tumor immunity through affecting series of processes including maturation, migration, antigen presentation and T-cell activation.
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RBPJ in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RBPJ in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.430.128
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.7690.7
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1860.904
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.070.824
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1660.929
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0570.982
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1730.676
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1090.956
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2490.909
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3230.837
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0120.662
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0630.302
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RBPJ in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RBPJ. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RBPJ. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RBPJ.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RBPJ. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RBPJ expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RBPJ and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRBPJ
Namerecombination signal binding protein for immunoglobulin kappa J region
Aliases IGKJRB; RBPJK; KBF2; RBP-J; CBF1; suppressor of hairless homolog (Drosophila); IGKJRB1; RBPSUH; recombining ......
Chromosomal Location4p15.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RBPJ collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.